Human embryonic stem cell (hESC)-based cell therapy depends on access to surplus embryos from IVF cycles and collaborative interactions between biomedical researchers and reproductive medicine professionals. It is becoming instrumental to achieve an international consensus about the standards that should regulate the manipulation of human embryonic tissue in two distinct settings: reproductive medicine and embryonic stem cell research. Within hESC research, the regulatory framework needs to be adjusted according to the actual expectations and potential detrimental consequences of hESC research.